



**Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
07 March 2026 :: Issue 835**

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....

Strategic Advisory Group of Experts on Immunization (SAGE) - March 2026

9 – 12 March 2026

This meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will be held from Monday to Thursday.

:: [Agenda](#)

:: [Declaration of Interest - Draft](#)

:: [SAGE Yellow Book – March 2026](#)

.....

.....

National/Regional Vaccine Production – Argentina

PAHO announces technology transfer agreement in Argentina to strengthen regional production of seasonal influenza vaccines

The agreement between CSL Seqirus and Sinergium, supported by PAHO, will establish a cell-based platform for influenza vaccine production in the country.

Buenos Aires, March 6, 2026 (PAHO) — The Pan American Health Organization (PAHO) announced a **technology transfer agreement for the cell-based production of seasonal influenza vaccines**, coordinated with CSL Seqirus, using technology developed at its facility in the United States, and Sinergium, based in Argentina.

This initiative will modernize and strengthen local and regional vaccine production capacity by incorporating a more advanced platform than those traditionally used. The announcement was made during a visit to Argentina by PAHO Director Dr. Jarbas Barbosa.

“Regional vaccine production is an essential component of health security in the Americas. This agreement represents a concrete step to strengthen the region’s technological capacity, reduce external dependencies, and improve our preparedness for future epidemics and pandemics,” Barbosa said..

The agreement builds on the experience of PAHO’s Regional Revolving Funds in planning and consolidating vaccine demand across the region, as well as coordinating with countries, which helps ensure greater predictability and sustainability in access to these health technologies.

Thanks to **PAHO’s strategy to strengthen regional vaccine manufacturing, Argentina now supplies about half of the seasonal influenza vaccines purchased for countries in the Americas through PAHO’s Revolving Fund**, compared with only 8% previously. In addition, through pooled procurement and larger purchase volumes, the price of the vaccine produced in the country has decreased by approximately 15%. The agreement positions Argentina as a strategic supplier in the Americas and contributes to strengthening regional competitiveness in vaccine production..

The new platform is expected to become operational around 2028, with an estimated production capacity of up to 400 million doses annually, once it reaches full operation.

The proposed strategy and efforts to expand regional production of other vaccines, such as PCV20 and hepatitis A, together with seasonal influenza vaccines, could generate exports for the country of up to \$250 million annually through the Revolving Funds. With four-year multi-year commitments, exports could reach \$1 billion in advanced biological products.

This initiative is part of PAHO's technical cooperation agenda to strengthen health resilience in the region. In Argentina, it builds on recent progress, including the introduction of the PCV20 vaccine through the Revolving Fund, support for a local mRNA vaccine development project, and the signing of agreements with the country's 24 jurisdictions to facilitate their participation in PAHO's Strategic Fund. These actions support a national agenda aimed at expanding production, availability, and equitable access to critical health tools.



National/Regional Vaccine Production – Nigeria

Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience

Research Open access

Godspower Onavbavba, Obi Peter Adigwe, Diana Oyin-mieyebi Wilson & Erica Chiamaka Ene

Health Research Policy and Systems, Published: 05 March 2026 <https://doi.org/10.1186/s12961-026-01442-z>

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract

Background

The lack of local production of vaccines in Nigeria is a challenge contributing to limited access to healthcare. To address these vulnerabilities, the nation has committed efforts toward vaccine self-sufficiency through local production. However, this initiative has been met with a plethora of constraints. These include inadequate technical capacity, insufficient resources, limited infrastructure, procurement challenges, cold chain management, uncertain market mechanisms and a lack of funding. This study, therefore, aims to bridge this gap by articulating robust strategies for local vaccine production from the perspective of relevant stakeholders across different areas of the vaccine value chain.

Methods

A qualitative strategy was adopted to explore participants' perspectives on the strategies for sustainable local vaccine manufacturing in Nigeria. The study sample represented stakeholders practising across different areas of the vaccine value chain. Data obtained were analysed thematically to yield themes and sub-themes. Trustworthiness in the study was ensured through recommended frameworks.

Results

Following data analysis, nine overarching themes were identified, which articulated the need to build capacity and an enabling environment for vaccine development in Nigeria. The findings showed that inadequate research capacity, weak infrastructure and poor commercialization frameworks constrain vaccine production, necessitating phased production initiation, strengthened research systems, infrastructural development and improved market access. Effective management and advocacy were found to be critical for securing government and stakeholders' commitment, as well as reducing vaccine hesitancy to support sustainable local vaccine production.

Conclusions

This study provides in-depth insights into the strategies for expediting the national objective to achieve vaccine self-sufficiency, including the establishment of an enabling policy and legislative environment to attract investment, streamline regulation and secure market access for locally produced vaccines. It emphasizes strengthening research and development capacity beyond fill-and-finish activities, addressing workforce skills gaps through training and technology transfer, and improving infrastructure through reliable power supply and vaccine industrial parks. Overall, the findings highlight the need for sustainable financing, stakeholder coordination, and strong government interventions to ensure the viability of local vaccine manufacturing. These insights can guide effective planning and comprehensive efforts into the requisite areas necessary for sustainable vaccine manufacturing in the country.

.....
.....

“Vaccine Sovereignty” – U.K.

[Vaccine Sovereignty as a Strategy for the UK’s Future Health, Wealth and National Security](#)

Paper 27th February 2026 Multiple Authors

Tony Blair Institute for Global Change

[Excerpts]

Foreword

The Covid-19 pandemic was one of the most significant global events of our time. It exposed how deeply health security, economic stability and national security are intertwined – and how vulnerable the UK becomes when it cannot reliably access critical medical countermeasures at speed.

The response to Covid demonstrated what the UK can achieve when government, the NHS, industry and communities act together. The rapid development and deployment of vaccines, led by the Vaccine Taskforce, was a defining success. Backing multiple vaccine platforms (each with a different mechanism of action against Covid-19), taking early financial risks and partnering closely with industry ensured that the UK was not dependent on a single scientific or commercial pathway. That approach saved lives and shortened a period of profound social and economic disruption.

But the pandemic also revealed a harder truth: scientific excellence alone is not enough. The UK lacked the domestic manufacturing capacity and end-to-end capability needed to translate innovation into doses at scale under intense global pressure. Supply chains for raw materials, specialist equipment and finished vaccines proved fragile and highly concentrated overseas. In a new world of rising geopolitical tension, export restrictions and competition for scarce resources, those vulnerabilities are not hypothetical: they are real and structural.

The lesson is clear: vaccine sovereignty is not about isolation or self-sufficiency, but strategic resilience. The UK must be able to act quickly and independently in a crisis, while remaining a reliable partner to allies. That requires sustained investment in domestic capability, alongside deepened international collaboration with trusted partners.

This matters because the risk has not receded. A future pandemic is not a question of if but when. As human activity increasingly intersects with previously undisturbed ecosystems, the probability of novel pathogens is rising. Future threats might not be best addressed by mRNA vaccines alone, but potentially by other platforms such as viral vectors, protein subunits, virus-like particles or technologies yet to be developed. Relying on a single platform, or just-in-time contract manufacturing, introduces avoidable risks. In addition, global markets are unlikely to function perfectly in a major public-health emergency.

As this paper shows, the cost of complacency is severe. **Disinvestment in pandemic preparedness would result in significantly higher deaths, hospitalisations and economic damage in a future Covid-scale event, which would drive higher public borrowing and deeper, longer-lasting disruption.** By contrast, targeted investment in preparedness, vaccine development and manufacturing capacity materially reduces both human and economic costs, while strengthening the UK's life-sciences sector and anchoring high-skilled jobs.

This report argues that vaccine sovereignty must be treated as a core component of national security. It calls for a hybrid approach: marshalling existing domestic capabilities into a coherent sovereign manufacturing core; building allied surge capacity through international partnerships; and targeting investment to remove critical bottlenecks across the vaccine pipeline.

Conclusion

The UK's success in deploying Covid-19 vaccines at speed in 2020 was not the product of a fully sovereign system, but of a uniquely favourable alignment of circumstances: early access to innovation, goodwill from global partners, temporarily open supply chains and exceptional regulatory flexibility. Those conditions no longer hold. The geopolitical environment is more fragmented, biological risks are more diverse and competition for critical inputs is sharper. In future crises, access to vaccines and their components cannot be assumed to be timely, equitable or insulated from political pressure.

Vaccine sovereignty must therefore be understood as a core element of national resilience, not as an industrial ambition or a contingency plan. It is about preserving agency, choice and autonomy when markets fail, supply chains fracture or other states prioritise their own interests. Countries that lack credible sovereign options in these moments risk delayed response, constrained policy choices and exposure to coercion at precisely the point of greatest vulnerability.

The global examples examined in this paper demonstrate that sovereignty does not require full self-sufficiency. Instead it rests on a combination of domestic anchors, warm-lit capacity, legal authority, priority access rights and trusted alliances. The most resilient systems institutionalise preparedness in non-pandemic times, align industrial capability with health-security objectives and ensure that the state retains the ability to act decisively in extremis.

This points to a blended model for the UK. Domestically the UK should marshal and coordinate existing manufacturing capability through a UK FAB-style arrangement that preserves platform diversity, sustains skills and guarantees surge access. Internationally it should embed itself within allied manufacturing networks, such as the EU FAB or a broader Global FAB construct, to secure additional scale and redundancy without inefficient duplication of capacity. Together, these approaches would restore strategic depth while remaining fiscally and industrially realistic.

Crucially this is not a one-off investment decision but a long-term strategic commitment. Manufacturing capability, regulatory readiness, workforce skills and supply-chain resilience all take years to build and cannot be recreated at speed once lost. Sustained, predictable investment and clear governance are therefore as important as physical infrastructure.

Ultimately, vaccine sovereignty is a political choice. It reflects a judgement that the premium associated with domestic capability and preparedness is justified by the value of independence, speed and security in future crises. For the UK, making that choice now would help ensure that when the next biological shock arrives, the country is not left to rely on favourable circumstances, but equipped with the capability, authority and partnerships needed to protect its

population, economy and national security.

.....
.....
.....

Polio – PHEIC

Polio this week [04 March 2026]

Headlines [Selected]

:: Celebrating International Women’s Day and special webinar

:: Impact of current regional situation in Afghanistan and Pakistan on polio eradication efforts

Any escalation of conflict brings insecurity and humanitarian consequences and risks for affected populations. The deteriorating security situations in parts of Pakistan and Afghanistan, as well as areas of the Gulf, is deeply concerning — particularly for children, whose health and access to essential services are often the first to be disrupted. At present, the evolving regional tensions have not directly impacted polio eradication operations in Pakistan and Afghanistan. The programmes remain operational, and preparations for upcoming supplementary immunization activities (SIAs) in April, are continuing. The situation is being closely monitored in coordination with national authorities and partners...

Summary of new polioviruses this week:

:: Pakistan: two WPV1-positive environmental samples

:: Chad: one cVDPV2 case

:: Malawi: one cVDPV2-positive environmental sample

:: Nigeria: four cVDPV2 cases

:: Somalia: one cVDPV2-positive environmental sample

.....

Statement of the Forty-fourth Meeting of the Polio IHR Emergency Committee

4 March 2026 *Statement* Geneva

[Excerpts]

The 44th meeting of the Emergency Committee under the International Health Regulations (IHR or Regulations) on the international spread of poliovirus was convened by the WHO Director-General on 14 January 2026 with eight out of nine Committee members and the adviser meeting via video conference with affected countries, supported by the WHO Secretariat.

The Emergency Committee reviewed the latest epidemiological data on wild poliovirus type 1 (WPV1) and circulating vaccine-derived polioviruses (cVDPV) in the context of the global targets to interrupt endemic WPV1 transmission in 2026 and to stop cVDPV2 outbreaks by 2028 with subsequent certification of WPV1 eradication and cVDPV2 elimination. Technical updates were received about the situation in the following countries: Afghanistan, Angola, Germany, Lao People’s Democratic Republic, Namibia, Pakistan and Papua New Guinea.

Amendments to the IHR, adopted by the Seventy-seventh World Health Assembly, through resolution WHA77.17 in June 2024, entered into force, generally, on 19 September 2025.. **Key amendments to the IHR include, inter alia, broader poliovirus notification requirements; the introduction of the determination of “pandemic emergency” , a higher level of global public health alert with respect to a public health emergency of international concern (PHEIC); measures to**

strengthen equitable access to relevant health products; and recognition of health documents in non-digital and digital formats...

Conclusion

- 1. The Committee unanimously concluded that the risk of international spread of polioviruses continues to constitute a Public Health Emergency of International Concern (PHEIC)** and recommended extending the Temporary Recommendations for a further three months.
- The Committee, after a thorough review of the epidemiological and programmatic situation, unanimously concluded that the event **does not constitute a *pandemic emergency*...**

...Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee's assessment, and on 01 March 2026 determined that the poliovirus situation continues to constitute a public health emergency of international concern (PHEIC) with respect to WPV1 and cVDPV. He further followed the advice of the Committee that the poliovirus situation does not constitute a pandemic emergency.

The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of polioviruses, effective, 01 March 2026.

.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

.....

.....

WHO & Regional Offices [07 Mar 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

6 March 2026 *Departmental update*

[Communities at the centre: advancing social and economic protection for preparedness and response](#)

4 March 2026 *News release*

[Chile becomes the first country in the Americas to be verified by WHO for the elimination of leprosy](#)

4 March 2026 *Statement*

[Statement of the Forty-fourth Meeting of the Polio IHR Emergency Committee](#)

3 March 2026 *Departmental update*

[WHO releases updated Health Inequality Data Repository and Health Equity Assessment Toolkit](#)

3 March 2026 *Departmental update*

[WHO calls for a global shift to environmentally friendly, less invasive and affordable oral health care](#)

2 March 2026 *Departmental update*

[Global webinar on core public health capacities to conduct ship inspections and issue ship sanitation certificates](#)

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 03 March 2026

[From data to decisions: strengthening health security in Africa](#)

:: 03 March 2026

[Sierra Leone surpasses HPV vaccination campaign targets, closes gap on cervical cancer elimination](#)

WHO Region of the Americas PAHO

:: 6 Mar 2026

[PAHO calls for intensified efforts to ensure safe motherhood in the Americas](#)

Washington, D.C., 6 March 2026 (PAHO) – On International Women’s Day, the Pan American Health Organization (PAHO) calls for accelerating efforts to reduce maternal mortality and ensure that all women in the Americas have access to essential health services, medicines, and technologies for safe motherhood. Despite progress in recent decades,...

:: 6 Mar 2026

[PAHO announces technology transfer agreement in Argentina to strengthen regional production of seasonal influenza vaccines](#)

The agreement between CSL Seqirus and Sinergium, supported by PAHO, will establish a cell-based platform for influenza vaccine production in the country. Buenos Aires, March 6, 2026 (PAHO) — The Pan American Health Organization (PAHO) announced a technology transfer agreement for the cell-based production of seasonal influenza vaccines, coordinated...

:: 5 Mar 2026

[Argentina joins Alliance for Primary Health Care](#)

Buenos Aires, March 5, 2026 (PAHO) — Today, Argentina joined the Alliance for Primary Health Care in the Americas (AxAPS), a regional initiative promoted by the Pan American Health Organization (PAHO), the World Bank (WB), and the Inter-American Development Bank (IDB) to accelerate the transformation of health systems through investment,...

:: 4 Mar 2026

[Chile becomes the first country in the Americas to be verified by WHO for the elimination](#)

[of leprosy](#)

PAHO/WHO Representative in Chile, Giovanni Escalante, and Chile's Minister of Health, Ximena Aguilera, during the ceremony recognizing the elimination of leprosy, held in Santiago, Chile. Santiago/Washington, D.C./Geneva, 4 March 2026- The World Health Organization (WHO), together with the Pan American Health Organization (PAHO), congratulates...

:: 3 Mar 2026

[PAHO calls for strengthened pharmacovigilance following reports of misuse of GLP-1 medicines indicated for treating obesity in adults](#)

Washington, DC, March 3, 2026 (PAHO) — The Pan American Health Organization (PAHO) urged countries in the Region of the Americas to strengthen monitoring and ensure the appropriate use of glucagon-like peptide-1 receptor agonist (GLP-1) medicines, in light of increasing reports of adverse events associated with their misuse. In an ...

:: 3 Mar 2026

[World Birth Defects Day: "Behind every diagnosis is a story that deserves to be supported through strong public policies and strengthened health systems"](#)

Interview with Pablo Durán, Regional Advisor on Perinatal and Neonatal Health at PAHO Washington, D.C., March 3, 2026 (PAHO) – Today marks World Birth Defects Day, an opportunity to raise awareness about a group of conditions that remain one of the leading causes of neonatal mortality and childhood disability in the Region of the Americas....

:: 2 Mar 2026

[Update on the review of measles elimination status](#)

Washington, D.C., 2 March 2026 (PAHO) — The Pan American Health Organization (PAHO) informs that the review of the measles elimination status in the United States and Mexico will take place in November 2026, during the Commission's regular annual meeting of the Regional Verification Commission for the Elimination of Measles, Rubella, and Congenital Rubella Syndrome (RVC). This review will include all Member States, with particular focus on those with active outbreaks and those that have completed one year of sustained transmission, in accordance with established criteria.

The decision to conduct these reviews during the regular annual meeting aims to simplify and harmonize the process within the Commission's regular schedule. In the case of the U.S., it also takes into account the ongoing analysis being conducted by its health authorities, which includes complete viral genome sequencing, including the development of a bioinformatics platform for detailed molecular data analysis, alongside ongoing efforts to support outbreak control...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 6 March 2026 *News release*

[WHO Country Office in Ukraine and ASEF support hospitals on the frontline](#)

3 March 2026 *News release*

[Over 6400 Ukrainians receive life-saving treatment abroad through medical evacuations](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 101, vol. 101, 9-10 [full issue] 6 March 2026

<https://iris.who.int/server/api/core/bitstreams/40da10d3-7418-4017-9de1-22723675247b/content>

:: Report of the Forty-ninth meeting (hybrid) of the WHO Global Advisory Committee on Vaccine Safety 27–28 November 2025

[Excerpt]

... *Vaccines and autism*

GACVS reviewed the evidence on vaccines Autism Spectrum Disorder (ASD) repeatedly between 2002 and 2012, consistently concluding that there was no credible evidence to support a causal link between vaccines and autism. Recent United States vaccine policy developments have, however, renewed discussion regarding vaccine safety and autism. Consequently, the Forty-ninth meeting of GACVS considered two recent evidence reviews – one on vaccines and ASD and one on aluminium as a vaccine constituent and serious conditions. While considering both reviews, Committee members focused their discussion on vaccines and autism in order to give strong advice on the relationship between vaccines and ASD.

The first review by Daniels et al., which included peer-reviewed scientific literature published between January 2010 and August 2025, focused on two questions: 1) “What is the relationship between thimerosal-containing vaccines and ASD?” and 2) “What is the relationship between vaccines and ASD?”¹

The findings for both research questions underscored that the most methodologically rigorous primary research studies do not support any causal association between vaccines, thimerosal-containing or otherwise, and ASD. GACVS members drew particular attention to the low strength of evidence and the high risk of bias in the studies claiming links between thiomersal and ASD.

The Committee also considered a Canadian review of articles that have assessed possible links between aluminium, which has been used in vaccines for almost a century, and systemic diseases such as ASD. That study concluded that available evidence does not support causal associations between aluminium-adjuvanted vaccines and chronic or systemic diseases such as ASD. The overall benefit–risk balance favours continued use of aluminium-adjuvanted vaccines.

GACVS members expressed agreement with the conclusions of the two systematic reviews and associated presentations. The GACVS members also noted that the recently published high quality Danish study² on aluminium adjuvants and vaccines is important as a large population-based study conducted in approximately 1.2 million children born in Denmark between 1997 and 2018. This study concluded that cumulative aluminum exposure from vaccination was not associated with increased rates of any of the disorders assessed, including ASD.

Although the Daniels et al. study used ASD as an outcome, GACVS members stressed there was no systematic characterization of the different elements of ASD. With the development of expanded diagnostic criteria (i.e. more inclusive of a clinical spectrum) and general awareness, there has been an increase in the incidence of autism diagnoses, but this may not necessarily reflect an increase in the incidence.

GACVS specifically noted that several studies reporting an association with vaccines or their ingredients had been conducted by the same small number of authors, had studied overlapping populations and had critical risk of bias and very low quality.

Although WHO had already issued a statement on the subject, GACVS members proposed drafting a statement on their assessment of their conclusions. GACVS members subsequently worked on a statement which has since been published.³

3. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) on vaccines and autism, 11 December 2025. Geneva: World Health Organization
<https://www.who.int/news/item/11-12-2025-statement-gacvs-vaccines-autism>

.....

New WHO Publications

<https://www.who.int/publications>

Selected

5 March 2026

[WHO guideline on environmentally friendly and less invasive oral health care for preventing and managing...](#)

2 March 2026

[Nurturing care for children with developmental delays and disabilities: thematic brief](#)

.....
.....
.....

Africa

Africa CDC [07 Mar 2026]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Release

[Africa CDC and Japan Institute for Health Security \(JIHS\) Sign Cooperation Agreement to Strengthen Global Health Security](#)

5 March 2026

...“Health threats cross borders, and preparedness depends on strong partnerships,” said Dr Jean Kaseya, Director General of Africa CDC. “This cooperation with JIHS will strengthen scientific collaboration, reinforce public health institutions and workforce capacity, and accelerate our ability to prevent, detect, and respond to outbreaks.”

The collaboration will also advance One Health and climate-resilient approaches to address zoonotic diseases, antimicrobial resistance, and other emerging risks...

.....
.....

China – CDC+

National Health Commission of the People's Republic of China [07 Mar 2026]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [07 Mar 2026]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2026-03-06 / No. 10 WOMEN'S HEALTH ISSUE

[PDF of this issue](#)

:: Foreword: Making Women's Health Visible: From Healthy Beginnings to System Resilience

Vital Surveillances: Longitudinal Trajectories of Growth and Development in HIV-Exposed Uninfected

Children from a Long-Term Birth Cohort — 8 Regions, 3 PLADs, China, 2017–2024

.....

.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Call for experts for Scientific Expert Panel on RSV vaccination in adults](#)

6 March 2026

The European Centre for Disease Prevention and Control (ECDC) has launched a call for experts to join a new Scientific Expert Panel (SEP) to support the development of an EU/EEA technical guidance on respiratory syncytial virus (RSV) vaccination to protect adults. The guidance, planned for publication in 2027, will provide evidence-based, non-binding recommendations to inform national immunisation strategies.

Surveillance and monitoring

[Communicable disease threats report, 28 February – 6 March 2026 , week 10](#)

6 March 2026

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[New guidance on the conduct of clinical trials during public health emergencies in the EU](#)

Recommendations to streamline authorisation of new clinical trials and changes to ongoing trials to generate clinical evidence

5 March 2026

.....

.....

India

National Centre for Disease Control

*Directorate General of Health Services, Ministry of Health & Family Welfare
Announcements
No new digest content identified.*

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

**Executive Branch - White House, State, HHS, FDA, CDC+
White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.*

Department of State

Press Releases - Selected

U.S. Embassy Harare Feb 25 [<https://x.com/USEmbZim>]

[The United States Regrets Government of Zimbabwe Decision on Health Assistance to Zimbabwe](#)

Harare, Zimbabwe, February 24, 2026 – The Government of Zimbabwe has communicated its decision to withdraw from negotiations on a proposed bilateral health Memorandum of Understanding (MOU) with the United States. This MOU would have provided \$367 million over five years to support Zimbabwe's priority health programs, including HIV/AIDS treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.

"We believe this collaboration would have delivered extraordinary benefits for Zimbabwean communities— especially the 1.2 million men, women, and children currently receiving HIV treatment through U.S.-supported programs," said U.S. Ambassador to Zimbabwe Pamela Tremont. "We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe."

The proposed MOU represented the largest potential health investment in Zimbabwe by any international funder and was built on a co-funding model designed to ensure sustainability and a path toward self-reliance. The MOU asked Zimbabwe to gradually increase its own health funding alongside U.S. support, building on more than \$1.9 billion in U.S. health support to Zimbabwe since 2006 that is directly responsible for Zimbabwe reaching the UNAIDS 95-95-95 goals.

Sixteen African countries have so far signed health collaboration MOUs with the United States, which represents over \$18.3 billion in new health funding including more than \$11.2 billion in U.S. assistance alongside \$7.1 billion in co-investment from recipient countries.

"The United States has a responsibility to American taxpayers to invest their resources where mutual accountability, transparency, and shared commitment are assured," Ambassador Tremont noted. "These MOUs set a higher standard for bilateral health cooperation—one that prioritizes sustainability, measurable outcomes, and shared ownership of results. The Government of Zimbabwe has assured us it is prepared to sustain the fight against HIV/AIDS, and we wish them well."

HHS

[Press Room](#) - Selected

No new digest content identified.

NIH [to 07 Mar 2026]

<http://www.nih.gov/>

[News Releases](#)

No new digest content identified.

FDA

[Press Announcements](#)

[FDA News Releases](#)

No new digest content identified.

FDA CBER

[What's New for Biologics](#)

No new digest content identified.

Divisive F.D.A. Vaccine Regulator Is Resigning

Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.

The New York Times, By Christina Jewett

March 6, 2026

Dr. Vinay Prasad, a polarizing figure at the Food and Drug Administration who oversaw vaccines, is leaving the agency at the end of April, according to a Health and Human Services spokesman.

As the agency's chief science and medical officer, Dr. Prasad had wide-ranging authority over vaccines, drugs and gene therapies. He issued several controversial decisions, including overruling career scientists on some vaccine approvals and cracking down on a biotech company linked to two teenagers's deaths.

In one of the most highly publicized moves, Dr. Prasad refused to accept Moderna's application for a new mRNA flu vaccine, causing an uproar among companies and some experts who complained he was too often moving the goal posts on studies that had been OK'd by the agency. Within days, Dr. Marty Makary, the agency's commissioner, reversed the decision after the company agreed to conduct another study...

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

Vaccines and Related Biological Products Advisory Committee - March 12, 2026

On March 12, 2026, the Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

No future meetings posted.

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified [last updated August 7, 2024]

ACIP

2026 Meetings Schedule

- **February 25-27** [*Cancelled without notice; no agenda content posted*]
- **March 18-19** [*No agenda content posted*]
- June 24-25
- October 21-22

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)
<https://www.hrsa.gov/advisory-committees/vaccines/meetings>
Next ACCV meetings – TBD

MMWR Weekly
<https://www.cdc.gov/mmwr/index2025.html>
Last edition published was January 1, 2026 / No. 42

.....

NSF
News
Website not available at inquiry.

.....

U.S. Congress
House of Representatives
No new digest content identified.

U.S. Senate
Senate Health, Education, Labor, and Pensions (HELP) Committee
No new digest content identified.

.....

Supreme Court, Federal & Appellate Courts

O’Neill Institute – Health Care Litigation Tracker [Georgetown University]
<https://litigationtracker.law.georgetown.edu/>
No new digest content identified.

.....
.....
.....

U.S. Medical, Professional Societies; Health Organizations
This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)
<https://www.aafp.org/news/media-center.html>
(Accessed 07 Mar 2026)
No new digest content identified.

American Academy of Pediatrics (AAP)
<https://www.aap.org/en/news-room/news-releases-from-the-aap/>
(Accessed 07 Mar 2026)
News
No new digest content identified.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 07 Mar 2026)

ACP News

[ACP advises all adults 75 or older get a protein subunit RSV vaccine](#)

In this population, RSV vaccination has been shown to reduce severe illness, hospitalization, and death
03/03/26

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 07 Mar 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 07 Mar 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 07 Mar 2026)

Press Releases

Mar 5, 2026

[Survey shows need to rebuild trust in evidence-based health information](#)

CHICAGO — New [survey findings](#) from the Annenberg Public Policy Center highlight a widening trust gap in the nation's health information landscape and underscore the importance of trusted medical voices grounded in science.

The survey found that physicians and medical organizations remain among the most trusted sources of public health information, with about 73% of Americans expressing confidence in the American Medical Association (AMA). The findings come at a time when confidence in federal health agencies has unfortunately declined, even as Americans continue to rely heavily on physicians and medical experts for credible, evidence-based information about health and disease prevention.

"Trust is the foundation of effective health care and public health," said AMA CEO John Whyte, MD, MPH. "In a challenging information environment, patients need clear, evidence-based guidance they can rely on. Physicians and medical organizations have a responsibility to help rebuild trust by communicating what the science shows and putting patients' health first. Health information is everywhere today, but its accuracy is harder than ever to determine. The AMA is dedicated to helping patients cut through the clutter and elevate the valid over the viral. Accurate, trustworthy information saves lives."

The AMA continues to advocate for science-driven health policy and clear communication grounded in the best available evidence to support patients and physicians. The AMA recognizes the need for a strong public health system that can foster and sustain a healthier future for everyone across our nation.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 07 Mar 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>

(Accessed 07 Mar 2026)

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 07 Mar 2026)

News releases and statements

No new digest content identified.

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 07 Mar 2026)

News and Updates

March 2, 2026

[Why Vaccines Are Especially Important for Older Adults](#)

Staying up to date on flu, RSV, pneumococcal, and other recommended vaccines can help protect older adults' health, independence, and community

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 07 Mar 2026)

Latest News

No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>

(Accessed 07 Mar 2026)

News & Announcements

No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>

(Accessed 07 Mar 2026)

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 07 Mar 2026)

News

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions [Selected]

.....

Kaiser Family Foundation/KFF [07 Mar 2026]

https://www.kff.org/search/?post_type=press-release

[KFF Tracker: America First MOU Bilateral Global Health Agreements](#)

Mar 2, 2026 *Tracker*

This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.

.....

Vaccine Integrity Project – CIDRAP [to 07 Mar 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements

[Vaccine Integrity Project kicks off evidence review of Tdap vaccine in pregnancy](#)

March 4, 2026

Mary Van Beusekom

.....

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>

[The Toilet Seat Challenge Test](#)

RFK Jr. snorted cocaine off toilet seats without suffering infections. He's no longer scared of germs.

Mar 03, 2026

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [07 Mar 2026]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

Gates Foundation [07 Mar 2026]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

CARB-X [07 Mar 2026]

<https://carb-x.org/>

News

03.04.2026 |

[CARB-X provides funding to Myers Research Group to develop antibiotic targeting drug-resistant pathogens](#)

CARB-X is awarding US\$1.2 million to the Andrew G. Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop enhanced antibiotics that target multi-drug-resistant Gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia, and bloodstream infections.

Chan Zuckerberg Initiative [07 Mar 2026]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [07 Mar 2026]

<http://cepi.net/>

CEPI News, Blog

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 07 Mar 2026]

<https://cioms.ch/>

News; Publications; Events

[Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT](#)

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences. Deadline to submit your comments is 13 March 2026.

DARPA – Defense Advanced Research Projects Agency [U.S.] [07 Mar 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [07 Mar 2026]

<https://dndi.org/press/press-releases/>

Press Releases

4 Mar 2026

[Pandemic preparedness: Novo Nordisk Foundation renews its support to DNDi and THSTI to continue the development of broad-spectrum antivirals](#)

The Novo Nordisk Foundation has awarded a grant of EUR 2,395,902 to the Drugs for Neglected Diseases initiative (DNDi) and India's Translational Health Science and Technology Institute (THSTI) to advance the development of a novel broad-spectrum antiviral candidate targeting influenza and other viruses of pandemic potential and strengthen pre-clinical research capacity for pandemic preparedness...

Duke Global Health Innovation Center [07 Mar 2026]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [07 Mar 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [07 Mar 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [07 Mar 2026]

<http://www.euvaccine.eu/>

News

No new digest content identified.

Fondation Merieux [07 Mar 2026]

<http://www.fondation-merieux.org/>

Actualités

4 mars 2026 *Dakar (Sénégal)*

[La Fondation Mérieux et RESAOLAB organisent un symposium sur le renforcement des systèmes de laboratoire en Afrique de l'Ouest](#)

Gates Medical Research Institute [07 Mar 2026]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications
No new digest content identified.

Gavi [to 07 Mar 2026]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GE2P2 Global Foundation [07 Mar 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 06 Feb 2026](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

GHIT Fund [07 Mar 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 07 Mar 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [07 Mar 2026]

<https://www.glopid-r.org/>

News & Events

No new digest content identified.

Hilleman Laboratories [07 Mar 2026]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [07 Mar 2026]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [07 Mar 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [07 Mar 2026]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [07 Mar 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 07 Mar 2026]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

Ongoing Public Consultations	^
> E22 EWG General Considerations for Patient Preference Studies	
> M4Q(R2) EWG Revision of M4Q(R1)	

<https://www.ich.org/page/public-consultations>

ICRC [to 07 Mar 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

Statement 02-03-2026

[ICRC president: Widening hostilities across Middle East putting civilian lives in grave danger](#)

Geneva (ICRC) – The following is a statement from ICRC President Mirjana Spoljaric on the widening of hostilities across the Middle East.

IFFIm [07 Mar 2026]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 07 Mar 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

[IFRC warns harmful information is putting lives at risk during crises](#)

05/03/2026 | *Press release*

Geneva, 5 March 2026 – Harmful information is undermining life-saving humanitarian action at a time when disasters are affecting more people, more often, according to the World Disasters Report 2026, released today by the International Federation of Red Cross and Red Crescent Societies (IFRC)...

IPPS - International Pandemic Preparedness Secretariat [07 Mar 2026]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [07 Mar 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 07 Mar 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Blog

[Science advice is under strain and science must reform itself](#)

The International Science Council president says the gap between scientific and political cultures is a major challenge.

March 6, 2026

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

No new digest content identified.

IVAC [07 Mar 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [07 Mar 2026]

<http://www.ivi.int/>

IVI News & Announcements

[IVI and H3D Foundation partner to advance drug and vaccine research and scientific capacity in Africa](#)

5 March 2026 — The International Vaccine Institute (IVI) and the H3D Foundation have signed a partnership agreement to strengthen drug and vaccine research and development and scientific

capacity across Africa through collaboration in early-stage research, training and capacity strengthening, and information exchange aligned with shared innovation priorities.

The collaboration will engage regional platforms, including the Grand Challenges African Drug Discovery Accelerator (GC ADDA) and ACHIEVE Africa (Accelerating Health Innovation, Equity, and Development of Vaccines and Biologics in Africa), an initiative designed to build the continent's end-to-end research and development ecosystem for vaccines and therapeutics, share best practices, and support and connect efforts addressing unmet global health needs.

Johns Hopkins Center for Health Security [07 Mar 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 07 Mar 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 07 Mar 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

War and conflict

[**MSF adapts and scales up activities amid escalating Middle East conflict**](#)

Press Release 5 Mar 2026

Gaza-Israel war

[**Two years of attacks on hospitals in Gaza**](#)

Documentary 5 Mar 2026

National Academy of Medicine - USA [to 07 Mar 2026]

<https://nam.edu/programs/>

News, Stories, Insights

No new digest content identified.

National Academy of Medicine - USA [to 07 Mar 2026]

<https://nam.edu/programs/>

News, Stories, Insights

[**National Academy of Medicine Launches "Patient Safety in the Era of AI" Initiative to Harness AI for Breakthrough Improvement in Patient Safety**](#)

March 4, 2026

The National Academy of Medicine (NAM) today announced the formal launch of its new national initiative, [Patient Safety in the Era of AI](#), a dynamic effort to harness the promise of artificial intelligence to improve patient safety and prevent harm across all US health care delivery systems. The initiative kicked off with a [Steering Group](#) meeting in Washington, DC on March 3, 2026, where leaders from patient advocacy, health care, technology, policy, and payment convened to chart the course for strategic action...

PATH [07 Mar 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

No new digest content identified.

Sabin Vaccine Institute [07 Mar 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [07 Mar 2026]

<http://www.unaids.org/en>

News, Stories, Updates

Press Statement

[International Women's Day: Rights, justice, and action for women and girls](#)

GENEVA, 6 March — Globally, in 2024, around 4,000 adolescent girls and young women newly acquired HIV every week—3,300 of whom live in sub-Saharan Africa, where women and girls make up around two in every three new HIV infections...

Feature Story

[Evidence reveals cross-country price variation for the procurement of HIV treatment](#)

05 March 2026

UNAIDS has published its consolidated annual information on the cost of procuring antiretroviral (ARV) treatment based on data provided by countries through the UNAIDS Global AIDS Monitoring tool.

The consolidated evidence reveals that there is considerable cross-country price variation, particularly for second-line regimens where prices increase significantly with income level highlighting transition and sustainability risks in middle-income settings...

UNICEF [to 07 Mar 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Statement 05 March 2026

[The brutality of war measured in children's lives as hostilities escalate in Iran](#)

AMMAN, 5 March 2026 —, "UNICEF is deeply concerned about the deadly impact the ongoing military escalation in Iran is having on children. Approximately 180 children have reportedly been killed and many more injured. "Among the casualties are 168 girls killed when a strike hit the Shajareh Tayyebah girls' elementary school in Minab, in southern Iran, on 28 February,..."

Unitaid [07 Mar 2026]

<https://unitaid.org/>

News releases

[South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir](#)

05 March 2026

Vaccine Equity Cooperative [nee Initiative] [07 Mar 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [07 Mar 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [07 Mar 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[Vaccine Update Newsletter February 2026](#)

Wellcome Trust [07 Mar 2026]

<https://wellcome.org/>

News. Opinion, Reports

Website not responding at inquiry.

The Wistar Institute [to 07 Mar 2026]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest announcements identified.

World Bank [to 07 Mar 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [07 Mar 2026]

<https://www.wfpha.org/>

Blog, Events

[Bombing in Iran and the Middle East](#)

Mar 3, 2026

THE WFPHA Statement Condemning the Bombing in Iran and the Middle East The World Federation of Public Health Associations (WFPHA) strongly condemns the recent actions by Israel and the United States of America, which initiated an act of war that...

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

[World Medical Association Announces Appointment of Dr Ramin Parsa-Parsi as Secretary General](#)

03.03.2026

The World Medical Association is pleased to announce that Dr Ramin Parsa-Parsi, MD, MPH, will assume the position of Secretary General of the World Medical Association, effective 1 May 2026.

Dr Parsa-Parsi, a physician with a Master of Public Health, brings extensive experience in global health, medical ethics, and international medical leadership. His career spans senior roles in national medical associations, governmental and multilateral institutions, and academia.

He has contributed significantly to the development of core WMA ethical instruments, supported physician self-governance worldwide, and played an important role in strengthening international health policy dialogue. We are confident that his expertise, vision, and long-standing commitment to the profession will reinforce the work of the WMA Secretariat in the years ahead.

As we welcome new leadership, we also extend our deepest appreciation to Dr Otmar Kloiber, who has served with exceptional dedication as Secretary General of the World Medical Association since 2005. Dr Kloiber's tenure has been marked by unwavering commitment to the global medical profession and to advancing the ethical foundations of medical practice...

World Organisation for Animal Health [OIE] [07 Mar 2026]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [07 Mar 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [07 Mar 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [07 Mar 2026]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [07 Mar 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [07 Mar 2026]

<https://ifpma.org/>

News & Resources

Position paper 4 Mar 2026

Artificial intelligence in pharmaceutical manufacturing – navigating innovation and regulation

Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming various sectors, and the pharmaceutical manufacturing industry is no exception. This paper explores how the pharmaceutical industry may use individual applications of AI in pharmaceutical manufacturing and control. It describes the evolving regulatory landscape and provides key considerations for national regulatory authorities (NRA) when reviewing...

International Alliance of Patients' Organizations – IAPO [07 Mar 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [07 Mar 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

Paul Chaplin Steps Down as CEO of Bavarian Nordic

COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO. Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014...

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.11/02/2026 –

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - Website not responding at inquiry.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

CSL Seqirus

News Releases - No new digest announcements identified.

Curevac

News - Website now directs to BioNTech site

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]
<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

03 March 2026

[GSK completes acquisition of RAPT Therapeutics](#)

GSK plc (LSE/NYSE: GSK) today announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases.

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - No new digest announcements identified.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

News and Blog Posts - No new digest announcements identified.

Nanogen

[News](#) - No new digest announcements identified.

Novartis

[News](#) - No new digest announcements identified.

Novavax

[Press Releases](#) - No new digest announcements identified.

Pfizer

[Recent Press Releases](#) - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

[Latest News](#) - No new digest announcements identified.

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Serum Institute

[News & Announcements](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified.

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

[Contents](#) [click to move among sections]

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Mar 05, 2026 Volume 113 Issue 3 p401-636

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

As genomic medicine is being increasingly integrated into healthcare systems, we're seeing a shift in workforce needs. More clinicians, genetic counselors, and scientists need specific training in variant interpretation, but education, training initiatives, and professional competencies are poorly defined. In this issue, Nisselle et al. developed learning outcomes for variant interpretation training, used these outcomes to inform both introductory and advanced education courses, and then evaluated program outcomes.

American Journal of Infection Control

March 2026 Volume 54 Issue 3 p241-368

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

March 2026 Volume 70 Issue 3

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

March 2026 116(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 114 (2026): Issue 2 (Feb 2026)

<https://www.ajtmh.org/view/journals/tpmd/114/2/tpmd.114.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

February 2026 Volume 179, Issue 2

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 351 February 2026

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/351/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 07 Mar 2026)

[Hospital-based vaccination of older adult inpatients: comparison of two delivery models for influenza, COVID-19 and pneumococcal vaccines](#)

Maria Lean, Garth Lean, Jeffrey J. Post
Research Open access 02 March 2026

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMC Public Health

<http://bmcpublikealth.biomedcentral.com/articles>

(Accessed 07 Mar 2026)

Articles

[Assessment of parental knowledge, attitude, and acceptance toward malaria vaccine for children under five years in Sudan, 2025](#)

Abdelfatah Abdelelah ElZain Hassan, Nafeesa Abdelgyum Hassan Ali, Samar Yousif Mohammed Awadallah

Research Open access 05 March 2026

[Vaccine hesitancy in the school community and among health personnel: a cross-sectional study](#)

Lely Stella Guzman-Barrera, Jaime Garcia, Fernanda Penido Matozinhos

Research Open access 03 March 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 07 Mar 2026)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2026 - Volume 31 - 1

<https://ebm.bmj.com/content/31/1>

[Reviewed earlier]

BMJ Global Health

February 2026 - Volume 11 - 2

<https://gh.bmj.com/content/11/2>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - January 2026

<https://thebulletin.org/magazine/2026-01/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 2, February 2026, 61-136

[Reviewed earlier]

Cell

Feb 19, 2026 Volume 189 Issue 4 p993-1262

<https://www.cell.com/cell/current>

[Reviewed earlier]

Cell and Gene Therapy Insights

February 2026 Issue, Volume 12 Issue 1

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1>

Editorial

[The next era of cell therapy](#)

Yu Cao 25 February

Child Care, Health and Development

Volume 52, Issue 2 March 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 119, Issue 2 Pages: 281-563 February 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

February 2026 Volume 48 Issue 2 p135-212

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 23 Issue 1, February 2026

<https://journals.sagepub.com/toc/ctja/23-1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 07 Mar 2026]

[Geographic disparities and determinants of DTP3 vaccination coverage among children aged 0–59 months in Somalia: a multilevel analysis](#)

Mohamed Abdirahim Omar, Mohamud Ali Mohamud, Abdisalam Hassan Muse

Research Open access 01 March 2026

In Somalia, a fragile state characterized by protracted conflict and fragmented health governance, childhood immunization remains a critical challenge. The third dose of the Diphtheria-Tetanus-Pertussis (DTP3) vaccine serves as a key indicator of health system performance and retention. This study aimed to identify structural and individual-level determinants of DTP3 coverage to understand the inequities in this humanitarian setting.

Contemporary Clinical Trials

Volume 162 March 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/162/suppl/C>

Research article Abstract only

[Increasing HPV vaccine promotion by dental providers: A clinical trial protocol](#)

D. Brad Rindal, Stephen Asche, Elyse Kharbanda, Bryan Michalowicz, ... Patricia L. Mabry

Article 108222

Research article Abstract only

[Increasing COVID-19 vaccine uptake through motivational interviewing-informed tailored digital intervention: Study protocol](#)

C.P. Ku, Alex Christian, Emerson Delacroix, Kirsten Trzeciak, ... Susie Williamson

Article 108221

The CRISPR Journal

Volume 8, Issue 6 / December 2025

<https://www.liebertpub.com/toc/crispr/8/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 12, 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2026 - Volume 39 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 07 Mar 2026]

[No new digest content identified]

Cytotherapy

March 2026 Volume 28 Issue 3

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 4 Pages: 253-323 December 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 2 March 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 20 - 2026

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

Original Research

[Beyond the After-Action Review: Expert Consensus for Military-Civilian Pandemic Planning](#)

Alysa Pomer, Vivitha Mani, Amanda Walsh, Christian L. Coles, Joel S. Weissman, Tracey Pérez

Koehlmoos, Eric Goralnick

Published online by Cambridge University Press:

11 February 2026, e35

Disasters

Volume 50, Issue 2 April 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 124 February 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/124/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 27, Issue 3 February 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-3>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 32, Number 2—February 2026

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 53 December 2025

<https://www.sciencedirect.com/journal/epidemics/vol/53/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 1 Pages: 1-48 January–February 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

Research and pregnant women • Considerations for informed consent

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 4 - Winter 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 36, Issue 1, February 2026

<https://academic.oup.com/eurpub/issue/36/1>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2026 Volume 105, Number 1

<https://www.foreignaffairs.com/issues/2026/105/1>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 07 Mar 2026]

Editorial

Published on 04 Mar 2026

[Editorial: Insights in human and medical genomics 2024](#)

Jared C. Roach, Maxim B. Freidin

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 07 Mar 2026]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 07 Mar 2026]

[No new digest content identified]

Gene Therapy – Nature

Volume 33 Issue 1, January 2026

<https://www.nature.com/qt/volumes/33/issues/1>

[Reviewed earlier]

Genetics in Medicines

Volume 28, Issue 2 February 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/2>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 07 Mar 2026]

[No new digest content identified]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 07 Mar 2026]

[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 07 Mar 2026]

[No new digest content identified]

Health and Human Rights

Volume 27, Issue 2, December 2025

<https://www.hhrjournal.org/volume-27-issue-2-december-2025/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 1 - January 2026

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 41, Issue 1, January 2026

<https://academic.oup.com/heapol/issue/41/1>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 07 Mar 2026]

[**Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience**](#)

Godspower Onavbavba, Obi Peter Adigwe, Erica Chiamaka Ene

Research Open access 05 March 2026

Human Gene Therapy

Volume 36, Issue 23-24 / December 2025

https://www.liebertpub.com/toc/hum/36/2_3-24

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 07 Mar 2026]

[No new digest content identified]

Immunity

Feb 10, 2026 Volume 59 Issue 2 p229-508

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 07 Mar 2026]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 07 Mar 2026]

[No new digest content identified]

International Health

Volume 18, Issue 2, March 2026

<https://academic.oup.com/inthealth/issue/18/2>

[**Examining wealth-related inequality in childhood vaccination in Fiji using the UNICEF Multiple Indicator Cluster Survey 2021**](#)

Connie Lam and others

[Oral cholera vaccine uptake, acceptance and confidence among residents of a high-risk township in Zambia: key insights for future vaccination programs](#)

Ernest Miti and others

Oral cholera vaccines (OCVs) prevent cholera and save lives. Given the recent 2024 country-wide cholera epidemic in Zambia, we determined self-reported OCV uptake, acceptance and confidence among adults living in a high-risk, cholera-prone township in Zambia.

International Human Rights Law Review

Volume 14 (2025): Issue 2 (Dec 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 13 No. 2 (2026): February 2026

<https://www.ijcmph.com/index.php/ijcmph/issue/view/133>

[New issue; No digest content identified]

International Journal of Epidemiology

Volume 55, Issue 1, February 2026

<https://academic.oup.com/ije/issue/55/1>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 5 4 November 2025

<https://www.emerald.com/ijhrh/issue/18/5>

[Reviewed earlier]

JAMA

March 3, 2026, Vol 335, No. 9, Pages 739-830

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns](#)

Marie-Joelle Jabagi, PharmD, PhD; Marion Bertrand, MSc; Amélie Gabet, PhD; et al.

JAMA. 2025;335(9):787-798. doi:10.1001/jama.2025.24082

This population-based study used data from the French National Health Data System to compare risk associations for respiratory syncytial virus (RSV)–related infant hospitalization and other outcomes after use of maternal vaccination with the respiratory syncytial virus prefusion F protein (RSVpreF) vaccine or passive infant immunization with nirsevimab.

JAMA Health Forum

March 2026, Vol 7, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue: No digest content identified]

JAMA Pediatrics

February 2026, Vol 180, No. 2, Pages 123-222

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

February 2026 - Volume 24 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

February 2026 Volume 78 Issue 2 p203-370

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 51, Issue 1 February 2026

<https://link.springer.com/journal/10900/volumes-and-issues/51-1>

[New issue: No digest content identified]

Journal of Development Economics

Volume 180 March 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/180/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 21 Issue 1-2, April 2026

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2026 - Volume 80 - 3

<https://jech.bmj.com/content/80/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 4 December 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>
[Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 3 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 37, Number 1, February 2026

<https://muse.jhu.edu/issue/56408>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 28, Issue 1 February 2026

<https://link.springer.com/journal/10903/volumes-and-issues/28-1>

[New issue; No digest content identified]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 1 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 1 Pages: 1-191 January 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 53 - Issue 4 - Winter 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

[New issue; No digest content identified]

Journal of Medical Ethics

March 2026 - Volume 52 - 3

<http://jme.bmj.com/content/current>

Editorial

[**Data for dollars? The ethics of trading African health data for American investment: lessons from the US–Kenya deal**](#) (27 February, 2026) Free

Keymanthri Moodley, Brian D Earp

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 290 March 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/290/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=toCList>

[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2026 - Volume 32 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 4 December 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

Volume 23, Issue 236 1 March 2026

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 33, Issue 2, March 2026

<https://academic.oup.com/jtm/issue>

[New issue; No digest content identified]

The Lancet

Mar 07, 2026 Volume 407 Number 10532 p915-1028

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[**Gender equality and equity: essential for health and society**](#)

The Lancet

The Lancet Child & Adolescent Health

Feb 2026 Volume 10 Number 2 p71-146, e4-e9

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2026 Volume 8 Number 1

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Feb 2026 Volume 14 Number 2 e173-e310

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Feb 2026 Volume 26 Number 2 p111-212, e77-e131

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Feb 2026 Volume 11 Number 2 e69-e136

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Feb 2026 Volume 14 Number 2 p99-186, e9-e18

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 12 December 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 2, February 2026

<https://journals.sagepub.com/toc/MDM/current>

[New issue; No digest content identified]

Medical Law International

Volume 25 Issue 4, December 2025

<https://journals.sagepub.com/toc/MLI/current>

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 103, Issue 4 Pages: 941-1223 December 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Mar 04, 2026 Volume 34 Issue 3 p1293-1868
<https://www.cell.com/molecular-therapy/current>
[New issue; No digest content identified]

Nature

Volume 651 Issue 8104, 5 March 2026
<https://www.nature.com/nature/volumes/650/issues/8104>
EDITORIAL 04 March 2026

[Funding from individual donors: lessons from the Epstein case](#)

Universities need to establish and empower compliance teams to ensure adherence to ethical funding policies.

Nature Biotechnology

Volume 44 Issue 2, February 2026
<https://www.nature.com/nbt/volumes/44/issues/2>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 07 Mar 2026)
[Reviewed earlier]

Nature Genetics

Volume 58 Issue 2, February 2026
<https://www.nature.com/ng/volumes/58/issues/2>
[Reviewed earlier]

Nature Human Behaviour

Volume 10 Issue 1, January 2026
<https://www.nature.com/nathumbehav/volumes/10/issues/1>
[Reviewed earlier]

Nature Medicine

Volume 32 Issue 2, February 2026
<https://www.nature.com/nm/volumes/32/issues/2>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 25 Issue 2, February 2026
<https://www.nature.com/nrd/volumes/25/issues/2>
[Reviewed earlier]

Nature Reviews Genetics

Volume 27 Issue 2, February 2026
<https://www.nature.com/nrg/volumes/27/issues/2>
[Reviewed earlier]

Nature Reviews Immunology

Volume 26 Issue 2, February 2026
<https://www.nature.com/nri/volumes/26/issues/2>
[Reviewed earlier]

New England Journal of Medicine Volume

Volume 394 No. 10 March 5, 2026
<https://www.nejm.org/toc/nejm/medical-journal>
[New issue; No digest content identified]

NEJM Evidence

Volume 5 No. 3 March 2026
<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

Public Health Alerts

[In Partnership with CIDRAP: Seasonal Influenza Activity, Vaccination Rates, and Pediatric Influenza Mortality, Massachusetts 2024–2025](#)

C.M. Brown and Others

njp Vaccines

<https://www.nature.com/njpvaccines/>
[Accessed 07 Mar 2026]
[No new digest content identified]

Pediatrics

Volume 157, Issue 3 March 2026
<https://publications.aap.org/pediatrics/issue/157/3>
Health Policy Article

[Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants](#)

Sean Tsung, MS; Yan Bo Zeng, BA, BS; Kevan Shah, MSc, MSM; Steven M. Asch, MD; Joshua A. Salomon, PhD ...

*From the American Academy of Pediatrics
Policy Statement*

[Recommended Childhood and Adolescent Immunization Schedule: United States, 2026: Policy Statement](#)

Sean T. O'Leary, MD, MPH, FAAP; Committee on Infectious Diseases

PharmacoEconomics

Volume 44, Issue 3 March 2026

<https://link.springer.com/journal/40273/volumes-and-issues/44-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 07 Mar 2026)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 07 Mar 2026)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 07 Mar 2026)

[Knowledge, attitudes and factors associated with the awareness of caregivers of under-five children regarding the malaria vaccine in the Tiko Health District, Cameroon: A community-based cross-sectional study](#)

Maureen Abiache Idang, Divine Nsobinyui, Chrisantus Eweh Ukah, Larissa Kumenyuy Yunika, Claudia Ngeha Ngu, Randolph Fuanghene Wefuan, Syveline Zuh Dang, Ndip Esther Ndip, Mirabelle Pandong Feguem, Claudine Muli Shei, Dickson S. Nsagha

Research Article | published 04 Mar 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004659>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 07 Mar 2026)

[From crisis response to country control: Restoring agency and sustainability in global health](#)

Ebere Okereke

Perspective | published 03 Mar 2026 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004961>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 07 Mar 2026)

[Adult dengue vaccination in a low transmission setting: A modelling study in Singapore](#)

Abhishek Senapati, Tun-Linn Thein, Yee-Sin Leo, Hannah Eleanor Clapham

Research Article | published 02 Mar 2026 PLOS Neglected Tropical Diseases
<https://doi.org/10.1371/journal.pntd.0014062>

PLoS One

<http://www.plosone.org/>

[Accessed 07 Mar 2026]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 07 Mar 2026]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

March 3, 2026 vol. 123 no. 9

<https://www.pnas.org/toc/pnas/123/9>

Opinion February 25, 2026 Front Matter

[In the wake of USAID cuts, we can create a Demographic and Health Survey Program founded on more equitable data infrastructure and stronger research integrity](#)

Jasmin Abdel Ghany, et al.

PNAS Nexus

Volume 5, Issue 1, January 2026

<https://academic.oup.com/pnasnexus/issue/5/1>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 41 - Issue 1 - 2026

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 203 February 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/203/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

Volume 293, Issue 2065 February 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 252 March 2026

<https://www.sciencedirect.com/journal/public-health/vol/252/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2026, Vol. 29, No. 1

<https://karger.com/phg/issue/29/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025

<https://journals.sagepub.com/toc/phrg/140/5-6>

[Reviewed earlier]

Qualitative Health Research

Volume 36 Issue 2-3, March 2026

<https://journals.sagepub.com/toc/QHR/current>

Editorial

[**Addressing the Special Issue: Intersections \(Existing, Emerging, and Imagined\) Between Artificial Intelligence and Qualitative Health Research**](#)

Johanna Creswell Báez, James Salvo, Jessica Nina Lester

Research Ethics

Volume 22 Issue 1, January 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 07 Mar 2026]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 46, Issue 3 March 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 07 Mar 2026]

[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 3 1 March 2026

<https://royalsocietypublishing.org/toc/rsos/current>

[New issue; No digest content identified]

Science

Volume 391| Issue 6789| 5 Mar 2026

<https://www.science.org/toc/science/current>

Editorial

[Sabotaging the NSF fellowship is a blunder](#)

BY H. Holden Thorp

05 Mar 2026

Policy Forum

[Governing real-world health data as a public utility](#)

BY Melissa A. Haendel, et al.

05 Mar 2026: 993-996

Abstract

It can take many years for evidence generated in research to influence health care guidelines (1). Meanwhile, the vast data collected during everyday life, particularly during engagement with the health care system, remain largely untapped for public health, precision medicine, postmarket safety, and real-time decision-making (2, 3). These “real-world data” (RWD) remain fragmented, proprietary, noninteroperable, and inconsistently governed. Although some approaches to RWD have demonstrated value in limited settings, their impact has remained constrained by uneven incentives, voluntary compliance, and the absence of routine auditability of data access and use. To address this, health data should be governed through federated, standards-based, community-driven models that reflect their public benefit, empower patients and communities, and foster public trust and participation. To help achieve these goals, we propose governing health data as essential infrastructure by using public utility models, defined by their public good, distributed stewardship, and public oversight.

Science and Engineering Ethics

Volume 32, Issue 2 April 2026

<https://link.springer.com/journal/11948/volumes-and-issues/32-2>

[Reviewed earlier]

Science Translational Medicine

Volume 18| Issue 838| 25 Feb 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 07 Mar 2026]

[No new digest content identified]

Social Science & Medicine

Volume 393 March 2026

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/393/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 07 Mar 2026]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 47, Issue 1 February 2026

<https://link.springer.com/journal/11017/volumes-and-issues/47-1>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 69 January–February 2026

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/69/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 31, Issue 2 Pages: 113-234 February 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 75 7 March 2026

<https://www.sciencedirect.com/journal/vaccine/vol/75/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 07 Mar 2026]

Open Access Review

[A Comparative Review of Veterinary and Human Vaccine Development Strategies: Insights into Herpesvirus Vaccinology from Latency to Elimination](#)

by Guangyi Liu, Xiaoyang Zhao, Yuezhi Lin, Xiaojun Wang and Diqiu Liu

Vaccines 2026, 14(3), 249; <https://doi.org/10.3390/vaccines14030249> (registering DOI) - 7 Mar 2026

Abstract

Background: Members of the virus family Herpesviridae are among the most successful pathogen groups in evolutionary history. They not only pose a serious public health threat to humans but also cause significant economic losses in the global livestock industry. The primary immunological challenge [..]

Open Access Article

[Real-World Vaccination Data Analysis for Three Vaccines Among Individuals Aged 60 and Older in Shanghai, China](#)

by Juan Li, Mingzhu Lin, Yong Feng, Wanran Cheng, Cuiping Zhou, Shaotan Xiao, Pengfei Deng and Laibao Yang

Vaccines 2026, 14(3), 246; <https://doi.org/10.3390/vaccines14030246> (registering DOI) - 7 Mar 2026

Abstract

Background: Vaccines targeting herpes zoster, influenza, and pneumococcal diseases represent the most effective interventions for reducing morbidity and mortality in individuals aged ≥ 65 years. This study employs real-world vaccination data for herpes zoster vaccine (HZV), influenza vaccine (InfV), and 23-valent pneumococcal polysaccharide [...]

Open Access Article

[Safety of Sabin-Strain Inactivated Poliovirus Vaccine Administered Alone or Concomitantly with Other Vaccines: A Population-Based Post-Marketing Surveillance Study](#)

by Lin Chang, Yuxi Liu, Yuan Ren, Jing Li, Xing Fang and Yurong Li

Vaccines 2026, 14(3), 241; <https://doi.org/10.3390/vaccines14030241> - 6 Mar 2026

Abstract

Background/Objectives: Sabin-strain inactivated poliovirus vaccine has been increasingly incorporated into routine immunization programs as part of the global strategy to eradicate poliomyelitis. As childhood immunization schedules become more complex, concerns persist regarding the safety of concomitant vaccination. Although randomized controlled trials and [...]

Open Access Article

[Exploring Parental Hesitancy and Acceptance of HPV Vaccination in a Saudi Population](#)

by Arwa Khaled, Khalid Orayj, Hend Talkhan, Retaj Ali, Altaf Alfifi, Shahad Bin Ghamia and Naglaa Bazan

Vaccines 2026, 14(3), 229; <https://doi.org/10.3390/vaccines14030229> - 28 Feb 2026

Abstract

Background: Human papillomavirus (HPV) vaccination is a major concern and highly effective strategy for preventing cervical cancer and other related diseases. Despite the inclusion of the HPV vaccine in the Saudi national immunization program and recent school-based initiatives, vaccine uptake remains suboptimal, mainly [...]

Value in Health

February 2026 Volume 29 Issue 2 p175-346

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

World Development

Volume 200 April 2026

<https://www.sciencedirect.com/journal/world-development/vol/200/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 07 Mar 2026]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[No new digest content identified]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 07 Mar 2026]

[Filter: *All articles*]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 07 Mar 2026]

[Digital monitoring and action planning to reach zero-dose and under-immunised children: Leveraging data for targeted immunisation responses](#)

Mariam Zahid Malik, Naeem uddin Mian, Zahid Memon, Muhammad Wasim Mirza, Umer Farooq Rana, M. Adeel Alvi, Wardah Ahmed, Asma Ummad, Ammarah Ali, Usama Naveed, Khayyam Saeed Malik, Muhammad Sufyan Chaudhary, Maria Waheed, Amna Sattar

medRxiv 2026.03.03.26346932; doi: <https://doi.org/10.64898/2026.03.03.26346932>

[PerTexP: scenario-based exploration of pertussis dynamics under maternal and infant vaccination](#)

Anna Autoriello, Sabrina Averga, Bruno Buonomo, Rossella Della Marca, Alfredo Guarino, Cristina Moracas, Emanuela Penitente, Marco Poeta

medRxiv 2026.03.05.26347721; doi: <https://doi.org/10.64898/2026.03.05.26347721>

[Securitized Health and Zero-Dose Children: Structural and Service-Contact Determinants of Non-Vaccination in Nigeria Paper I](#)

Ibrahim Mohammed

medRxiv 2026.03.02.26347396; doi: <https://doi.org/10.64898/2026.03.02.26347396>

[A model-based evaluation of the cost-effectiveness of paediatric and elderly vaccination against pneumococcal infection in England](#)

Matt J. Keeling, Omar El Deeb, Phuong Bich Tran, Stavros Petrou, Edward M. Hill

medRxiv 2026.02.26.26347158; doi: <https://doi.org/10.64898/2026.02.26.26347158>

[The long-term impact and effectiveness of rotavirus vaccination in Malawi: an interrupted time-series and case-control analysis](#)

Latif Ndeketa, Virginia E. Pitzer, Khuzwayo C. Jere, Aisleen Bennett, Nigel A. Cunliffe, Peter J. Dodd, Neil French, Daniel Hungerford

medRxiv 2026.02.27.26346681; doi: <https://doi.org/10.64898/2026.02.27.26346681>

[The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes](#)

Ruchira R Khosavanna, Sapon Iamsirithaworn, Soontorn Pinpaiboon, Kanyarat Phutthasophit, Taweewun Hunsawong, Albert I Ko, Kathryn B Anderson, Darunee Buddhari

medRxiv 2026.02.26.26347232; doi: <https://doi.org/10.64898/2026.02.26.26347232>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 07 Mar 2026]

Case Study Open Access

[Community-based participatory research as a process of engagement with underserved groups at risk of viral hepatitis in HCMC, Vietnam](#)

[version 1; peer review: awaiting peer review]

Giang Nguyen Quoc, et al.

Addressing community health issues requires an integration of community-driven initiatives with more traditional academic research. The CBPR approach facilitated a comprehensive assessment, the implementation of context-specific interventions, and engagement with and empowering of communities related to care seeking. The CBPR process required capacity-building activities, a flexible timeframe, patience, and the creation of opportunities for the community to exercise self-determination, especially during the COVID-19 pandemic.

uptake in the future. The sentiments by city findings may help in the design of future research.

* * * *

[Think Tanks](#)

Brookings [to 07 Mar 2026]

<http://www.brookings.edu/>

Research, Events
No new digest content identified.

Center for Global Development [07 Mar 2026]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 07 Mar 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [07 Mar 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 07 Mar 2026]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

IS Global [to 07 Mar 2026]

<https://www.isglobal.org/en/>

Newsroom

No new digest content identified.

McKinsey Global Institute [to 07 Mar 2026]

<https://www.mckinsey.com/mgi/overview>

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 07 Mar 2026]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 07 Mar 2026]

<https://www.pewresearch.org/>

Latest Publications

No new digest content identified.

Rand [to 07 Mar 2026]
<https://www.rand.org/pubs.html>
Published Research [Selected]
No new digest content identified.

Urban Institute [to 07 Mar 2026]
<https://www.urban.org/research>
New Research Publications - Selected
No new digest content identified.

World Economic Forum [to 07 Mar 2026]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

[Request for Information on Draft NIH Controlled-Access Data Policy and Proposed Revisions to NIH Genomic Data](#)

NATIONAL INSTITUTES OF HEALTH (NIH) Notice Number: NOT-OD-26-023 **Response Date: March 18, 2026**

Purpose

The National Institutes of Health (NIH) is requesting public input on its proposal to establish harmonized and transparent policy requirements for protecting human participant research data. Specifically, NIH proposes (1) establishing policy requirements for which data should be controlled-access under NIH data sharing policies, and (2) revising the NIH Genomic Data Sharing Policy to simplify and harmonize requirements.

Background

NIH serves as the steward of a wide range of research data and continuously works to optimize open sharing with appropriate protections throughout the entire data lifecycle. Given its numerous established data policies, NIH is proposing a holistic update to its data policy framework to strengthen data protections, clarify requirements, and reduce duplicative burden. NIH is proposing a new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations. This proposed policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types. It also provides a standard set of expectations across NIH Institutes, Centers and Offices to promote maximal responsible human participant data sharing through controlled access while simultaneously responding to emergent privacy and security risks, including those outlined in the following security directives...

[Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT](#)

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences.

Medicines are public health tools. With regard to the quality and transparency of the assessment of their effectiveness and safety, they are increasingly subject to the expectations and requirements of

patients, healthcare professionals and regulators. Those involved in the development and delivery of medicines must therefore take full account of the aforementioned paradigm shifts. Additionally, the arrival of novel therapeutic agents, such as gene therapy, biologics and mRNA vaccines, whose modes of action and interactions with living organisms have very little in common with those of the more traditional chemical medicines, has brought into question the classic elements of pharmacovigilance and pharmacoepidemiology, such as the dose–effect relationship, drug causation criteria and the determination of drug exposure.

CIOMS full [concept note on Pharmacoepidemiology for Public Health](#)

You are invited to review and comment on the draft report entitled *Realising the Potential of Pharmacoepidemiology for Public Health Decision-Making*. [Download the report here](#).

Please note that comments will only be considered when using the [template provided here](#). The **deadline to submit your comments is 13 March 2026**.

* * * *

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *